Why the study?
The efficacy of the automatic implantable cardioverter-defibrillator in preventing sudden death in high-risk patients with drug-refractory ventricular tachyarrhythmias needed assessment.
Does the automatic implantable cardioverter-defibrillator prevent sudden death in patients with drug-refractory ventricular tachyarrhythmias?
Cohort (n=78)
Nonrandomized
No
Does the automatic implantable cardioverter-defibrillator prevent sudden death in patients with drug-refractory ventricular tachyarrhythmias?
The automatic implantable cardioverter-defibrillator significantly reduces the risk of sudden death in patients with drug-refractory ventricular tachyarrhythmias who present with loss of consciousness.
Answers are grounded in this paper and cite their sources.
Supports ICD consideration in drug-refractory VT with syncope; leaves open randomized confirmation of survival benefit.
Study objective To assess the efficacy of the automatic implantable cardioverter-defibrillator in preventing sudden death in high-risk patients. Design Nonrandomized cohort study. Setting A university teaching hospital with 500 beds. Patients Consecutive sample of 78 patients with symptomatic, sustained ventricular tachyarrhythmias that were previously drug-refractory. Interventions Before February 1985, patients received treatment with the defibrillator and amiodarone if they presented with loss of consciousness (group A) and amiodarone alone if they did not lose consciousness (group C). After February 1985, because the availability of the defibrillator was severely curtailed, patients who lost consciousness received treatment with amiodarone alone (group B). Measurements and main results The risk for recurrent arrhythmias was similar between groups. The actuarial risk for sudden death in group B was 31% (95% confidence interval, 11% to 51%) at 1 and 2 years, a value that was significantly higher than that for group A (p less than 0.003) or group C (p less than 0.03). The risk for dying suddenly with the first recurrence was 0.78 in group B, a value that was significantly higher than that for group A (p less than 0.003) or group C (p less than 0.002). Conclusion The defibrillator is highly effective in preventing sudden death in patients whose presenting arrhythmias caused loss of consciousness (group A). In patients whose presenting arrhythmias did not result in loss of consciousness (group C), initial treatment with the defibrillator appears unnecessary.
No takes yet. Share an insight, caveat, or question.
Richard N. Fogoros (1987) conducted a cohort in Symptomatic, sustained, drug-refractory ventricular tachyarrhythmias (n=78). Automatic implantable cardioverter-defibrillator plus amiodarone vs. Amiodarone alone was evaluated on Actuarial risk for sudden death at 1 and 2 years (95% CI 11-51, p=<0.003).
Synapse has enriched 10 related papers. Consider them for comparative context: